Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma?

Leukemia and Lymphoma

Volumn 50, Issue 11, 2009, Pages 1733-1734

  Eichenauer, Dennis A ^a,b   Engert, Andreas ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER RELAPSE; DRUG EFFICACY; HODGKIN DISEASE; HUMAN; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HODGKIN DISEASE; HUMANS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; PROCARBAZINE; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 71049187591     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903308098     Document Type: Note

References (10)

1. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395.
2. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 Study. J Clin Oncol 2009; epub ahead of print.
3. Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005;16:124-131.
4. Borchmann P, Engert A, Pluetschow A, et al. Dose-intensified combined modality treatment with 2 cycles of BEACOPPescalated followed by 2 cycles of ABVD and involved-field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) Blood 2008;112:367 (Abstract).
5. Ruffer JU, Ballova V, Glossmann J, et al. BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkin's disease - results of the German Hodgkin Study Group. Leuk Lymphoma 2005;46:1561-1567.
6. Sieniawski M, Franklin J, Nogova L, et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 2007;25:2000-2005.
7. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002;359:2065-2071.
8. Cavalieri E, Matturro A, Annechini G, et al. Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma. Leuk Lymphoma 2009;50:1803-1808.
9. Aleman BM, van den Belt-Dusebout AW, De BruinML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878-1886.
10. Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supraadditive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008;49:1486-1493.